FDA Mulls Chalk-Like Additive for Candies, Cakes, and Cow Juice
Published Date: 9/25/2026
Proposed Rule
Summary
Doehler GmbH has asked the FDA to allow calcium sulfate to be safely used in foods like coated candies, dry milk, and baked goods. This change would update the rules to match good manufacturing practices, helping food makers use this ingredient without extra fuss. The petition was filed on September 10, 2026, and could affect food producers and consumers by ensuring safe, regulated use of calcium sulfate.
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
Allow calcium sulfate in specific foods
Doehler GmbH has asked FDA to amend the color additive rules to allow calcium sulfate to be used, at levels consistent with good manufacturing practice, in coated candies; dry milk; whey products; powdered creamers; and icings and baked good fillings. The petition was filed on September 10, 2026, and, if granted, would let food makers use this ingredient in those listed products under FDA rules.
Proposed regulated safe use for consumers
The petition asks FDA to provide for the safe use of calcium sulfate in food at levels consistent with good manufacturing practice, which means the ingredient would be allowed under FDA regulation intended to protect people who eat those foods. The petition was filed on September 10, 2026.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
2026-19654, Naveed Aslam: Final Debarment Order
The FDA has permanently banned Dr. Naveed Aslam from working with any drug companies because he was convicted of a serious crime related to drug regulations. He didn’t respond to the FDA’s notice or ask for a hearing, so the ban started on September 25, 2026. Dr. Aslam can apply to end this ban anytime, but it won’t be easy or quick.
2026-19660, Reauthorization of the Biosimilar User Fee Act; Public Meeting; Request for Comments
The FDA is gearing up to renew the Biosimilar User Fee Act, which helps fund the review of biosimilar drug applications. This affects drug makers and the public by ensuring faster, smoother approval processes from 2028 to 2032. They’re hosting a public meeting on October 26, 2026, and want your comments by November 25, 2026, to shape the future of this important program.
Previous / Next Documents
Previous: 2026-19642, Department of Justice; Response to Correspondence Requesting Rulemaking
The Department of Justice reviewed 10 requests asking them to create new rules but decided not to make any changes. This affects people interested in immigration and law enforcement rules, with no new costs or deadlines announced. The DOJ is sticking with current rules and legal decisions for now.
Next: 2026-19667, Air Plan Approval; Kentucky; Campbell-Clermont Area Maintenance Plan for the 2010 1-Hour SO2 NAAQS
The EPA is proposing to approve Kentucky’s plan to keep the air clean from sulfur dioxide pollution in the Campbell-Clermont area for another 10 years. This plan shows Kentucky can maintain safe air quality without extra costs or big changes. People living and working in this area can expect continued healthy air, with public comments open until October 26, 2026.